Stockscreener 앱 받기
0.9435
3.34%
-0.0326
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Quince Therapeutics, Inc. Files 8-K/A Amendment to Correct Reverse Stock Split Description – Key SEC Filing Details - Minichart
Quince Therapeutics (QNCX) confirms 1-for-20 reverse split and sharp share reduction - Stock Titan
1-for-20 reverse split consolidates Quince Therapeutics (NASDAQ: QNCX) shares - Stock Titan
Price to sales forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Enterprise value to revenue forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Price to book forward of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics, Inc. Actuals & Estimates (NASDAQ:QNCX) - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating By Investing.com - Investing.com South Africa
QNCX Forecast — Price Target — Prediction for 2027 - TradingView
Cantor Fitzgerald reiterates Quince Therapeutics stock Overweight rating - Investing.com
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Quince Therapeutics stock rating at Overweight - Investing.com
QNCX Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Leerink Partners Initiates Quince Therapeutics at Outperform With $4 Price Target - marketscreener.com
Leerink initiates Quince Therapeutics stock with Outperform rating - Investing.com
QNCX Initiated Coverage by Cantor Fitzgerald -- Rating Set to Ov - GuruFocus
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating - Investing.com UK
Cantor Fitzgerald initiates Quince Therapeutics stock with overweight rating By Investing.com - Investing.com South Africa
Quince Therapeutics Inc. (QNCX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
Cantor Fitzgerald Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Quince Therapeutics Inc (QNCX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Quince Therapeutics Stockbackground, strategy and long-term outlook - Ad-hoc-news.de
QUINCE THERAPEUTICS INC (QNCX) Stock Chart - ChartMill
Quince Therapeutics Inc (QNCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Quince Therapeutics Inc (QNCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Quince Therapeutics Inc (QNCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Quince Therapeutics Inc (QNCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Quince Therapeutics Inc (QNCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Quince Therapeutics Inc (QNCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Quince Therapeutics Inc (QNCX) Institutional Confidence - TradingKey
Quince Therapeutics (QNCX) director granted stock options for 2,700 shares - Stock Titan
Quince Therapeutics (QNCX) director receives 2,700 stock options grant - Stock Titan
Number of shareholders of Quince Therapeutics, Inc. – NASDAQ:QNCX - TradingView
Quince Therapeutics (QNCX) Approves Reverse Stock Split—SEC 8-K Filing Details (June 11, 2026) - Minichart
Quince Therapeutics Stock (US74833Q1004): Stock in focus after shareholder analyst call - Ad-hoc-news.de
Quince Therapeutics (QNCX) officer awarded multi-million share option grants - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) files Form 3 for officer Brigette Roberts - Stock Titan
Quince Therapeutics (NASDAQ: QNCX) wins approval for wide reverse split range - Stock Titan
Quince Therapeutics, Inc. announced that it has received $115.000298 million in funding from a group of investors - marketscreener.com
[SCHEDULE 13G] Quince Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
QNCX Q1 2026 Earnings: Unexpected Profit Driven by One-Time Items; Shares DipSurprise Factor Analysis - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Massive EPS Surprise Driven by Non-Operating Items, Stock DeclinesNet Profit Margin - newsline.com
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Insider Monkey
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
Quince Therapeutics stock (US74833Q1004): Nasdaq-listed biotech rebounds after regaining compliance - AD HOC NEWS
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics (QNCX) Edges Higher: Navigating Key Levels Near ResistanceCovered Call ETF - newsline.com
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by Over 200% - thelegaladvocate.com
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights
Quince Therapeutics regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com
Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
1.36%
자본화:
|
볼륨(24시간):